Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health systems costs and quality of life estimates
dc.contributor.author | Ong, KJ | |
dc.contributor.author | Checci, M | |
dc.contributor.author | Burns, Lorna | |
dc.contributor.author | Pavitt, C | |
dc.contributor.author | Postma, M | |
dc.contributor.author | Jit, M | |
dc.date.accessioned | 2018-10-13T18:10:46Z | |
dc.date.issued | 2019-02 | |
dc.identifier.issn | 1368-4973 | |
dc.identifier.issn | 1472-3263 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/12504 | |
dc.description.abstract |
<jats:sec><jats:title>Background</jats:title><jats:p>Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider’s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124–US$883 (anogenital warts), US$6912–US$52 579 (head and neck cancers), US$12 936–US$51 571 (anal cancer), US$17 524–34 258 (vaginal cancer), US$14 686–US$28 502 (vulvar cancer) and US$9975–US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).</jats:p><jats:p>Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.</jats:p></jats:sec> | |
dc.format.extent | 28-35 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | BMJ Publishing Group | |
dc.subject | HPV | |
dc.subject | cost-effectiveness | |
dc.subject | meta-analysis | |
dc.subject | systematic reviews | |
dc.subject | vaccination | |
dc.subject | Anus Diseases | |
dc.subject | Anus Neoplasms | |
dc.subject | Condylomata Acuminata | |
dc.subject | Cost-Benefit Analysis | |
dc.subject | Female | |
dc.subject | Genital Diseases, Female | |
dc.subject | Genital Diseases, Male | |
dc.subject | Head and Neck Neoplasms | |
dc.subject | Health Care Costs | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Papillomavirus Infections | |
dc.subject | Papillomavirus Vaccines | |
dc.subject | Penile Neoplasms | |
dc.subject | Quality of Life | |
dc.subject | Respiratory Tract Infections | |
dc.subject | United States | |
dc.subject | Vaginal Neoplasms | |
dc.subject | Vulvar Neoplasms | |
dc.title | Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health systems costs and quality of life estimates | |
dc.type | journal-article | |
dc.type | Journal Article | |
dc.type | Systematic Review | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471867000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 1 | |
plymouth.volume | 95 | |
plymouth.publication-status | Published | |
plymouth.journal | Sexually Transmitted Infections | |
dc.identifier.doi | 10.1136/sextrans-2018-053606 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Dental School | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Community and Primary Care | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Health and Community | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2018-08-07 | |
dc.rights.embargodate | 2019-3-8 | |
dc.identifier.eissn | 1472-3263 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1136/sextrans-2018-053606 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-02 | |
rioxxterms.type | Journal Article/Review |